Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection (FMT)
Primary Purpose
Clostridium Difficile
Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Fecal Microbiota Transplantation
Sponsored by
About this trial
This is an interventional treatment trial for Clostridium Difficile focused on measuring C-diff, Clostridium difficile, Fecal Transplant, FMT, Fecal Microbiota Transplant
Eligibility Criteria
Inclusion Criteria:
Recipient inclusion criteria:
- Documented laboratory-confirmed clostridium difficile infection
- Documentation of ongoing diarrhea at time of recruitment
- Children ≥2 years old, <18 years old; young adults >18 years old, <21 years old
- Undergoing clinically-indicated colonoscopy
- Recurrent c-diff infection (three or more occurrences)
Donor inclusion criteria:
- First-degree relative recommended, but not compulsory
- ≥ 18 years old
- In good health
- No antibiotic use within the last 90 days
- In "low risk" category on modified DHQ (See above)
Exclusion Criteria:
- Recipient exclusion criteria
- Severe comorbid condition (at discretion of the principal investigator)
- On immunosuppressive medications (high dose steroids 30 mg/kg of methylprednisolone)
Severe or fulminant C. difficile colitis
- Toxic appearance
- Signs of hemodynamic instability
- Peritoneal signs on physical exam
- Anemia on complete blood count
- electrolyte imbalances on basic metabolic panel
- Considerations for Increased Risk of Adverse Events Should Be Given to patients with decompensated liver cirrhosis, advanced HIV/acquired immune deficiency syndrome, recent bone marrow transplant, or other cause of severe immunodeficiency.
- History of severe anaphylactic shock
Donor exclusion criteria:
- Abnormal stools
- Abdominal complaints
- History of inflammatory bowel disease or gastrointestinal malignancy
- Symptoms indicative of irritable bowel syndrome or other chronic pain syndromes (e.g. chronic fatigue syndrome, fibromyalgia)
- History of systemic autoimmunity (e.g. multiple sclerosis, connective tissue disease)
- Recent use of potent immunosuppressive medications (calcineurin inhibitors, exogenous glucocorticoids, biological agents, etc..)
- Recent ingestion of a potential allergen (e.g. nuts) where recipient has a known allergy to this (these) agent(s)
- Known communicable disease
- Neurologic, neurodevelopmental or neurodegenerative disorders
- History of malignancy
- Has consumed any foods/medications to which the recipient is allergic within the designated period of time
Sites / Locations
- GI Division, Nationwide Children's HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Fecal Microbiota Transplantation
Arm Description
250 ml of a fecal suspension diluted in saline given by colonoscopy or enema.
Outcomes
Primary Outcome Measures
Resolution of C. difficile
The primary objective of the study is to establish the cure rate of C. difficile infection in pediatric patients.
Secondary Outcome Measures
Adverse events
Follow up phone calls will be made at days 1, 7, 14, and months 1 and 6 to determine whether adverse events have occurred.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02134392
Brief Title
Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection
Acronym
FMT
Official Title
Fecal Microbiota Transplantation (FMT) for Recurrent or Refractory C. Difficile Infection (CDI) in Pediatric and Young Adult Patients
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 2013 (Actual)
Primary Completion Date
January 2025 (Anticipated)
Study Completion Date
January 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Jonathan Gisser
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
C-diff infection often causes belly pain and diarrhea and can be very hard to treat with medicine. One of the possible reasons that C-diff infection is hard to treat is because there is too much "bad" bacteria in the colon. Investigators believe that putting more "good" bacteria into the colon will help fight the "bad" bacteria. We do this by doing a fecal (poop) transplant.
Fecal transplant has been done at other hospitals, but not at Nationwide Children's Hospital. Since our Investigators have not done this before, this study will help us learn the best way to do the transplant. Investigators also believe this transplant might help improve symptoms for patients with C-diff.
Detailed Description
Visit 1 - screening visit: This visit will take about 1 hour. The study doctor will talk to the patient about C-diff infection and fecal transplant in detail. Investigators will ask you questions about your medical history and health. A complete physical examination will be done. Investigators will order a pregnancy test (for girls who are old enough to become pregnant) and take blood (about 1.5 teaspoons) to make sure you do not have any other illness or infections (other than C-diff.) If the pregnancy test comes back positive on a patient who is younger than age 18, both the patient and parent(s) will be informed. The study doctor will then choose a possible stool donor. The study doctor will ask the donor to fill out a questionnaire about their medical history, past and present diseases, allergies and medications. If this donor seems suitable, blood and stool tests will be performed on the donor.
Before the next visit: Before the fecal transplant is scheduled the study doctor will look at your all of the lab results from you and the donor to make sure it is safe for the fecal transplant to take place. This will take up to two weeks. If the donor is not a suitable donor, another donor will be chosen. Every possible donor will need to sign a consent form and fill out questionnaires. When a suitable donor is found, we will to schedule the fecal transplant.
There are two ways in which the fecal transplant can be given. One is by enema and the other is during a colonoscopy. The study doctor believes that the best way to give the transplant is during a colonoscopy. If you needs to have a colonoscopy done for clinical purposes (in the routine medical care of your C-diff infection), the fecal transplant will happen during that procedure. The doctor will explain the colonoscopy to you in detail and will be given special instructions on how to prepare for the colonoscopy. You will need to sign a separate consent for the colonoscopy. The other way the fecal transplant can be given is by enema. If you are not having a colonoscopy or for some other reason the doctor believes it is better to do so, you will receive the transplant through an enema.
The study doctor will talk with you about stopping medicines that are not allowed during the study. If you are taking antibiotics (such as metronidazole, vancomycin, or rifaximin, nitazoxanide, and fidaxomicin) as a treatment for C-diff, you will be asked to stop these medicines 2 days before the transplant.
Visit 2 - the day of the fecal transplant: This visit will take about 4-6 hours. A pregnancy test will be repeated. If the pregnancy test comes back positive for a patient who is younger than age, both the patient and parent will be informed. The study doctor will ask you and the donor how they are feeling. If either the patient or the donor is not feeling well, the transplant will be reschedule to another day. If both are well, the fecal transplant will proceed.
On the morning of the transplant the donor will be asked to have a bowel movement in a plastic container. The donor will bring this stool sample to the hospital to be processed. This stool sample will be blended into a liquid.
The FMT can be given by either a colonoscopy or enema. The doctor will talk to you about which method will be best for you.
Transplant by colonoscopy: Before the colonoscopy, the study doctor will ask questions about your symptoms and medications. During the colonoscopy, the doctor will squirt one cupful (250 ml) of liquid into the colon using a special colonoscopy tube. The liquid will be made of saline (salt water) and donor stool. The recovery time from the colonoscopy will be the same.
Transplant by enema: The study doctor will ask you questions about your symptoms and medications. The patient's pants and underwear will be removed. A thin slippery tube will be put into the patient's bottom (rectum). The tube will be pushed in as deep as we can without pushing the tube hard. About 1 cupful of liquid will be gently squeezed into the rectum. The liquid will be made of saline (salt water) and donor stool. We will ask the patient to lie down on their left side for 30 minutes and keep the solution in for at least 45 minutes. The patient will then be sent home.
After the transplant: The patient will be called at days 1, 7, 14 and months 1 and 6 to see how they are feeling. The investigator's staff will ask some questions over the phone. The phone call will take about 10 minutes. The patient may also call the study doctor anytime with questions or concerns.
If belly pain or diarrhea continues one month after the transplant, the study doctor will want to repeat a stool test for C-diff. Sometimes the patient is not cured and a second transplant is needed. If a second transplant is needed, the same donor can be used if he/she is willing. The second transplant will be done by enema. The donor would have lab (blood and stool tests) done again to be sure she/he does not have any new infections or illness.
The donor may need to have the lab work done again if the transplant does not happen as scheduled (cancellation, no-show or illness). HIV testing is one of the things we do on potential donors. The HIV testing must be done no more than 14 days before the transplant. The other required lab tests need to be done no more than 30 days before the transplant. The date the transplant is rescheduled to will determine whether or not these tests need to be done again.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Clostridium Difficile
Keywords
C-diff, Clostridium difficile, Fecal Transplant, FMT, Fecal Microbiota Transplant
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Fecal Microbiota Transplantation
Arm Type
Experimental
Arm Description
250 ml of a fecal suspension diluted in saline given by colonoscopy or enema.
Intervention Type
Biological
Intervention Name(s)
Fecal Microbiota Transplantation
Intervention Description
250 ml of a fecal suspension diluted in saline will be administered via colonoscopy or enema in patients with recurrent c-diff.
Primary Outcome Measure Information:
Title
Resolution of C. difficile
Description
The primary objective of the study is to establish the cure rate of C. difficile infection in pediatric patients.
Time Frame
6 months post transplant
Secondary Outcome Measure Information:
Title
Adverse events
Description
Follow up phone calls will be made at days 1, 7, 14, and months 1 and 6 to determine whether adverse events have occurred.
Time Frame
Six months post transplant
10. Eligibility
Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Recipient inclusion criteria:
Documented laboratory-confirmed clostridium difficile infection
Documentation of ongoing diarrhea at time of recruitment
Children ≥2 years old, <18 years old; young adults >18 years old, <21 years old
Undergoing clinically-indicated colonoscopy
Recurrent c-diff infection (three or more occurrences)
Donor inclusion criteria:
First-degree relative recommended, but not compulsory
≥ 18 years old
In good health
No antibiotic use within the last 90 days
In "low risk" category on modified DHQ (See above)
Exclusion Criteria:
Recipient exclusion criteria
Severe comorbid condition (at discretion of the principal investigator)
On immunosuppressive medications (high dose steroids 30 mg/kg of methylprednisolone)
Severe or fulminant C. difficile colitis
Toxic appearance
Signs of hemodynamic instability
Peritoneal signs on physical exam
Anemia on complete blood count
electrolyte imbalances on basic metabolic panel
Considerations for Increased Risk of Adverse Events Should Be Given to patients with decompensated liver cirrhosis, advanced HIV/acquired immune deficiency syndrome, recent bone marrow transplant, or other cause of severe immunodeficiency.
History of severe anaphylactic shock
Donor exclusion criteria:
Abnormal stools
Abdominal complaints
History of inflammatory bowel disease or gastrointestinal malignancy
Symptoms indicative of irritable bowel syndrome or other chronic pain syndromes (e.g. chronic fatigue syndrome, fibromyalgia)
History of systemic autoimmunity (e.g. multiple sclerosis, connective tissue disease)
Recent use of potent immunosuppressive medications (calcineurin inhibitors, exogenous glucocorticoids, biological agents, etc..)
Recent ingestion of a potential allergen (e.g. nuts) where recipient has a known allergy to this (these) agent(s)
Known communicable disease
Neurologic, neurodevelopmental or neurodegenerative disorders
History of malignancy
Has consumed any foods/medications to which the recipient is allergic within the designated period of time
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ling Fan, MPH
Phone
614-722-3412
Email
ling.fan@nationwidechildrens.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jonathan M. Gisser, M.D.
Organizational Affiliation
Nationwide Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
GI Division, Nationwide Children's Hospital
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43205
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jonathan M. Gisser, M.D.
Phone
614-355-2858
Email
jonathan.gisser@nationwidechildrens.org
First Name & Middle Initial & Last Name & Degree
Jonathan M. Gisser, M.D.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection
We'll reach out to this number within 24 hrs